Description
Springer Platinum Coordination Complexes in Cancer Chemotherapy 1983 1st Editon 2011 Softbound by Miles P. Hacker, Evan B. Douple, Irwin H. Krakoff
The idea for convening a Fourth International Symposium on Platinum Coordination Complexes in Cancer Chemotherapy was born in an assembly of researchers from the Vermont Regional Cancer Center and the Norris Cotton Cancer Center who shared a common interest in metal complexes. It was agreed by those assembled that sufficient time had passed since the Third International Symposium on Platinum Coor dination Complexes in Cancer Chemotherapy held in 1976 at the Wadley Institutes of Molecular Medicine in Dallas, Texas, during which several advances in the chemistry, biochemistry, pharmacology and clinical use of platinum complexes had occurred, to warrant a fourth symposium. Furthermore, intensive investigations in progress were bringing sophisticated methodologies to bear on the problems in the field, clinical trials were yielding interesting results, and unique approaches to cancer therapy were being designed. Therefore, an organizing committee was formed and planning culminated in the symposium which was held in Burlington, Vermont, June 22-24, 1983. Nomenclature.- Nomenclature for Platinum Antitumor Compounds.- Section I: Biochemistry of Platinum Coordination Complexes in Cancer Chemotherapy.- Overview.- Chemical and Biological Studies of cis-Diamminedichloroplatinum (II) Binding to DNA.- Is DNA the Real Target of Antitumor Platinum Compounds?.- Specific Binding of cis-Platinum Compounds to DNA and DNA Fragments.- Section II: Pharmacology and Pharmacodynamics of Platinum Coordination Complexes in Cancer Chemotherapy.- Overview.- Plasma Pharmacokinetics, Urinary Excretion, and Tissue Distribution of Platinum Following IV Administration of Cyclobutanedicarboxy—atoplatinum-II and cis-Platinum to Rabbits.- Clinical Pharmacokinetics of Diammine [1,1-Cyclobutanedicarboxylato-(2-)]-0,0?-Platinum (CBDCA).- Biliary Excretion, Renal Handling and Red Cell Uptake of Cisplatin and CBDCA in Animals.- Biodistribution and Pharmacokinetics of 195mpt-Labeled cis-Dichloro-trans-Dihydroxo-bis(Isopropylamine)-Platinum(IV), CHIP, in the Normal Female Fischer 344 Rat.- Clinical Pharmacokinetics of cis-Dichloro-trans-Dihydroxo-bis(Isopropylamine)Platinum(IV).- Disposition of Cisplatin vs Total Platinum in Animals and Man.- Section III: Toxicology of Platinum Coordination Complexes in Cancer Chemotherapy.- Overview.- Diethyldithiocarbamate and cis-Platinum Toxicity.- Selected Aspects of Cisplatin Nephrotoxicity in the Rat and Man.- Evaluation of Platinum Complexes for Emetic Potential.- Section IV: Development of New Platinum Coordination Complexes.- Overview.- Synthesis and Testing of Platinum Analogues — An Overview.- Experimental Antitumor Activity of Platinum Coordination Complexes.- JM8 Development and Clinical Projects.- Section V: Non-Platinum Metal Complexes As Antitumor Agents.- Structure Activity Relationship of Antitumor Palladium Complexes.- The Metallocene Dihalides — A Class of Organometallic Early Transition Metal Complexes as Antitumor Agents.- The Design of Metal Complexes as Anticancer Drugs.- Section VI: Unique Therapeutic Approaches Using Platinum Coordination Complexes.- Overview.- Phase I and Early Phase II Trials of 4? Carboxyphthalato (1,2 Diaminocyclohexane) Platinum (II).- High Dose Cisplatin in Hypertonic Saline: Renal Effects and Pharmacokinetics of a40 MG/M2 QD × 5 Schedule.- Clinical Experience with 1,1-Diaminomethylcyclohexane (Sulphato) Platinum (II) (TNO-6).- David B. Brown Memorial Lecture.- Cisplatin — Past, Present and Future.- Author Index.